BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsukuma S, Tokumitsu Y, Shindo Y, Matsui H, Nagano H. Essential updates to the surgical treatment of biliary tract cancer. Ann Gastroenterol Surg 2019;3:378-89. [PMID: 31346577 DOI: 10.1002/ags3.12266] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Oh MY, Kim H, Choi YJ, Byun Y, Han Y, Kang JS, Sohn H, Lee JM, Kwon W, Jang JY. Conversion surgery for initially unresectable extrahepatic biliary tract cancer. Ann Hepatobiliary Pancreat Surg 2021;25:349-57. [PMID: 34402435 DOI: 10.14701/ahbps.2021.25.3.349] [Reference Citation Analysis]
2 Rizzo A, Ricci AD, Brandi G. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun 2021;27:100337. [PMID: 33611090 DOI: 10.1016/j.ctarc.2021.100337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
3 Ruzzenente A, Bagante F, Olthof PB, Aldrighetti L, Alikhanov R, Cescon M, Koerkamp BG, Jarnagin WR, Nadalin S, Pratschke J, Schmelzle M, Sparrelid E, Lang H, Iacono C, van Gulik TM, Guglielmi A; Perihilar Cholangiocarcinoma Collaboration Group. Surgery for Bismuth-Corlette Type 4 Perihilar Cholangiocarcinoma: Results from a Western Multicenter Collaborative Group. Ann Surg Oncol 2021. [PMID: 33956275 DOI: 10.1245/s10434-021-09905-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun 2021;27:100356. [PMID: 33799004 DOI: 10.1016/j.ctarc.2021.100356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Shindo Y, Kobayashi S, Wada H, Tokumitsu Y, Matsukuma S, Matsui H, Nakajima M, Yoshida S, Iida M, Suzuki N, Takeda S, Hoshii Y, Eguchi H, Nagano H. Short- and Long-Term Outcomes of Simultaneous Hepatic Artery Resection and Reconstruction for Perihilar Cholangiocarcinoma. Gastrointest Tumors 2021;8:25-32. [PMID: 33728293 DOI: 10.1159/000511164] [Reference Citation Analysis]
6 Rizzo A, Ricci AD, Brandi G. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? Expert Review of Precision Medicine and Drug Development 2021;6:217-24. [DOI: 10.1080/23808993.2021.1915126] [Reference Citation Analysis]
7 Matsukuma S, Nagano H, Kobayashi S, Wada H, Seo S, Tsugawa D, Okuyama H, Iida K, Ohmura Y, Takeda Y, Miyamoto A, Nakashima S, Yamada T, Ajiki T, Tsuji A, Yoshimura K, Eguchi H, Hatano E, Ioka T; Kansai Hepato-Biliary Oncology (KHBO) Group. The impact of peritoneal lavage cytology in biliary tract cancer (KHBO1701): Kansai Hepato-Biliary Oncology Group. Cancer Rep (Hoboken) 2021;4:e1323. [PMID: 33283475 DOI: 10.1002/cnr2.1323] [Reference Citation Analysis]
8 Nara S, Esaki M, Ban D, Takamoto T, Mizui T, Shimada K. Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:537-45. [PMID: 33793366 DOI: 10.1080/17474124.2021.1911645] [Reference Citation Analysis]
9 Miyata Y, Kogure R, Nakazawa A, Nagata R, Mitsui T, Ninomiya R, Komagome M, Maki A, Kawarabayashi N, Beck Y. The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis. J Clin Med 2021;10:925. [PMID: 33804297 DOI: 10.3390/jcm10050925] [Reference Citation Analysis]
10 Rizzo A, Brandi G. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer Treat Res Commun 2021;27:100334. [PMID: 33592563 DOI: 10.1016/j.ctarc.2021.100334] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Umemura A, Nitta H, Takahara T, Hasegawa Y, Sugai T, Sasaki A. Central hepatic bisectionectomy with hepatic artery and biliary tracts reconstruction for the patient with nodular type intrahepatic hilar cholangiocarcinoma: A case report. Int J Surg Case Rep 2021;82:105868. [PMID: 33839628 DOI: 10.1016/j.ijscr.2021.105868] [Reference Citation Analysis]
12 Rizzo A, Ricci AD, Frega G, Di Federico A, Brandi G. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert Rev Gastroenterol Hepatol 2021;15:567-74. [PMID: 33787429 DOI: 10.1080/17474124.2021.1911646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ueno G, Iwagami Y, Kobayashi S, Mitsufuji S, Yamada D, Tomimaru Y, Akita H, Asaoka T, Noda T, Gotoh K, Mori M, Doki Y, Eguchi H. ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer. Ann Surg Oncol 2022. [PMID: 34994902 DOI: 10.1245/s10434-021-11152-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
15 Takihata Y, Einama T, Kobayashi K, Suzuki T, Yonamine N, Fujinuma I, Tsunenari T, Yamagishi Y, Iwasaki T, Miyata Y, Shinto E, Ogata S, Tsujimoto H, Ueno H, Kishi Y. Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma. Oncol Lett 2021;21:414. [PMID: 33841575 DOI: 10.3892/ol.2021.12675] [Reference Citation Analysis]
16 Tokumitsu Y, Shindo Y, Matsui H, Matsukuma S, Nakajima M, Yoshida S, Iida M, Suzuki N, Takeda S, Nagano H. Laparoscopic total biopsy for suspected gallbladder cancer: A case series. Health Sci Rep 2020;3:e156. [PMID: 32318627 DOI: 10.1002/hsr2.156] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]